Cover Image
Market Research Report

Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024

Published by Datamonitor Healthcare Product code 858221
Published Content info 546 Pages
Delivery time: 1-2 business days
Price
Back to Top
Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024
Published: June 7, 2018 Content info: 546 Pages
Description

OVERVIEW

Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular disease, one of the world's leading causes of morbidity and mortality. Other lipid level deviations in dyslipidemia include low levels of HDL-C, elevated total cholesterol, and elevated triglycerides.

MARKET SNAPSHOT

  • Generic erosion of key legacy product sales will be offset by the growth of the branded PCSK9 inhibitor class.
  • Datamonitor Healthcare's primary research survey of 238 physicians sheds light on prescribing patterns in dyslipidemia.
  • Dyslipidemia is a serious public health concern, as prevalence is high and it is a strong risk factor for CVD and CAD.
  • Positive CVOT data combined with steep discounts will drive PCSK9 uptake.
  • Inclisiran is a promising pipeline medication and has the opportunity to provide cost-effective PCSK9 inhibition.
  • Payers impose strict access controls on PCSK9 inhibitors.
Table of Contents
Product Code: DMKC4708

TABLE OF CONTENTS

FORECAST: DYSLIPIDEMIA (Published on 22 June 2018)

  • OVERVIEW
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: CRESTOR
  • PRODUCT PROFILE: JUXTAPID
  • PRODUCT PROFILE: KYNAMRO
  • PRODUCT PROFILE: LIPITOR
  • PRODUCT PROFILE: PRALUENT
  • PRODUCT PROFILE: REPATHA
  • PRODUCT PROFILE: ZETIA FRANCHISE
  • PRODUCT PROFILE (LATE STAGE): BEMPEDOIC ACID FRANCHISE
  • PRODUCT PROFILE (LATE STAGE): EVINACUMAB
  • PRODUCT PROFILE (LATE STAGE): INCLISIRAN
  • PRODUCT PROFILE (LATE STAGE): VOLANESORSEN

TREATMENT: DYSLIPIDEMIA (Published on 19 June 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN DYSLIPIDEMIA

EPIDEMIOLOGY: HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA (Published on 07 June 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • SUPPLEMENTARY ANALYSIS: DYSLIPIDEMIA IN THE US
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: DYSLIPIDEMIA (Published on 22 June 2018)

  • OVERVIEW
  • STATINS
  • PCSK9 INHIBITORS
  • FIBRATES
  • NIACINS
  • OMEGA-3 FATTY ACIDS
  • OTHER DRUG CLASSES
  • PRODUCT PROFILE: CRESTOR
  • PRODUCT PROFILE: EPANOVA
  • PRODUCT PROFILE: JUXTAPID
  • PRODUCT PROFILE: KYNAMRO
  • PRODUCT PROFILE: LIPITOR
  • PRODUCT PROFILE: LOVAZA
  • PRODUCT PROFILE: PRALUENT
  • PRODUCT PROFILE: REPATHA
  • PRODUCT PROFILE: VASCEPA
  • PRODUCT PROFILE: ZETIA FRANCHISE

PCSK9 INHIBITORS PRICING, REIMBURSEMENT, AND ACCESS (Published on 21 December 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PAYER INSIGHTS
  • US PRICING
  • US REIMBURSEMENT
  • JAPAN
  • FIVE MAJOR EU MARKETS PRICING
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY

PIPELINE: DYSLIPIDEMIA (Published on 22 June 2018)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • RECENTLY DISCONTINUED DRUGS
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): BEMPEDOIC ACID FRANCHISE
  • PRODUCT PROFILE (LATE STAGE): EVINACUMAB
  • PRODUCT PROFILE (LATE STAGE): INCLISIRAN
  • PRODUCT PROFILE (LATE STAGE): VOLANESORSEN
Back to Top